Allogene Therapeutics ($ALLO) Insider Trading & Smart Money Activity

Allogene Therapeutics, Inc. · Biotechnology · Latest filing Jun 18, 2026

Allogene Therapeutics, Inc. ($ALLO) has 1 insider trade and 2 13F position changes on file. Insiders filed 1 Form 4 transaction in the last 12 months, none of them open-market purchases or sales.

Insider buyers (12 mo)
0
Insider sellers (12 mo)
0
Net insider $ (12 mo)
$0
Congress trades (12 mo)
0
13F moves on file
2
Analyst ratings on file
0

ALLO insider buying and selling by quarter

QuarterInsider buysInsider salesCongress buys / sales13F added / cut
Q1 2026 0 0 0 / 0 0 / 0
Q2 2026 0 0 0 / 0 0 / 2
Q3 2026 0 0 0 / 0 0 / 0
Q4 2026 0 0 0 / 0 0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All ALLO insider, congress, 13F and analyst activity

DateSourceWhoActionSharesValue / amount ΔOwn1W1M6MFilingStory
Insider Stephen Mayo Buy (Grant or award) 144.40K sh +3.0%-11.5% Read
13F Two Sigma Advisers Sold out -2.89M sh 0.0%-3.0% —
13F Two Sigma Advisers Sold out -2.89M sh 0.0%-3.0% —

1W / 1M / 6M = how ALLO moved from the trade or filing date.

Insider trading in ALLO: who is buying and selling

InsiderRoleTradesOpen-market netShares heldLast trade
Stephen Mayo 1 — Jun 18, 2026

Institutions moving ALLO (13F)

Frequently asked questions

What is the latest insider trade in ALLO?

Stephen Mayo filed a buy (grant or award) of 144.40K sh on Jun 18, 2026.

Which institutions changed their ALLO positions?

Recent 13F filers moving the stock include Two Sigma Advisers.

Other biotechnology stocks

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text